Intervention1: Evobrutinib (M2951) 45mg administered orally twice daily: Blinding will be accomplished using a double dummy design given the differences in tablet characteristics between Evobrutinib a

2 trials

Sponsors

Merck Healthcare KGaA

Conditions

Health Condition 1: G00-G99- Diseases of the nervous systemHealth Condition 1: G35- Multiple sclerosis

Phase 3

Phase III Study of Evobrutinib in Relapsing Multiple Sclerosis

Active, not recruitingCTRI/2020/10/028183

Merck Healthcare KGaAHealth Condition 1: G35- Multiple sclerosis

Target: 930Updated: 2023-11-13

Phase III Study of Evobrutinib in patients with Relapsing Multiple Sclerosis(RMS)

Active, not recruitingCTRI/2020/10/028457

Merck Healthcare KGaAHealth Condition 1: G00-G99- Diseases of the nervous system

Target: 1124Updated: 2023-12-19